ASSESSING THE BENEFIT OF CONTINUOUS TREATMENT IN THE FIRST TRIAL (MM-020): IMPACT OF RESPONSE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

被引：0
|
作者：
Bahlis, N. [1 ]
Corso, A. [2 ]
Muegge, L. O. [3 ]
Shen, Z. X. [4 ]
Desjardins, P. [5 ]
Stoppa, A. M. [6 ]
Decaux, O. [7 ]
de Revel, T. [8 ]
Granell, M. [9 ]
Marit, G. [10 ]
Nahi, H. [11 ]
Demuynck, H. [12 ]
Huang, S. Y. [13 ]
Basu, S. [14 ]
Ervin-Haynes, A. [15 ]
Leupin, N. [15 ]
Marek, J. [15 ]
Chen, G. [15 ]
Facon, T. [16 ]
机构：
[1] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[2] Policlin San Mateo Univ Pavia, Pavia, Italy
[3] Univ Klinikum Jena, Klink Inner Med 2, Jena, Germany
[4] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai 200030, Peoples R China
[5] Hop Charles Lemoyne, Longueuil, PQ, Canada
[6] Inst J Paoli I Calmettes, F-13009 Marseille, France
[7] CHRU Hosp Sod Med Interne, Rennes, France
[8] Hop Instruct Armees Percy, Paris, France
[9] Hosp Santa Cree & St Pau, Barcelona, Spain
[10] CHU Bordeaux Hop Haut Leveque, Pessac, France
[11] Karolinska Univ, Huddinge Hosp, Solana, Sweden
[12] Jan Yperman Hosp VZW, Leper, Belgium
[13] Natl Taiwan Univ Hosp, Taipei, Taiwan
[14] New Cross Hosp, Wolverhampton, W Midlands, England
[15] Celgene Corp, Summit, NJ USA
[16] Hop Claude Huriez, Serv Malad Sang, Lille, France
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P277
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [31] Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
    Bahlis, N. J.
    Corso, A.
    Mugge, L-O
    Shen, Z-X
    Desjardins, P.
    Stoppa, A-M
    Decaux, O.
    de Revel, T.
    Granell, M.
    Marit, G.
    Nahi, H.
    Demuynck, H.
    Huang, S-Y
    Basu, S.
    Guthrie, T. H.
    Ervin-Haynes, A.
    Marek, J.
    Chen, G.
    Facon, T.
    LEUKEMIA, 2017, 31 (11) : 2435 - 2442
  • [32] Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
    N J Bahlis
    A Corso
    L-O Mugge
    Z-X Shen
    P Desjardins
    A-M Stoppa
    O Decaux
    T de Revel
    M Granell
    G Marit
    H Nahi
    H Demuynck
    S-Y Huang
    S Basu
    T H Guthrie
    A Ervin-Haynes
    J Marek
    G Chen
    T Facon
    Leukemia, 2017, 31 : 2435 - 2442
  • [33] Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
    Wang, Yan
    Liu, Yuan-Fang
    Jin, Shi-Wei
    Tao, Yi
    Zhang, Wei-Ping
    Chen, Jian-Lin
    Jiang, Song-Fu
    Mi, Jian-Qing
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [34] All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Dimopoulos, Meletios A.
    Grosicki, Sebastian
    Jedrzejczak, Wieslaw W.
    Nahi, Hareth
    Gruber, Astrid
    Hansson, Markus
    Gupta, Neeraj
    Byrne, Catriona
    Labotka, Richard
    Teng, Zhaoyang
    Yang, Huyuan
    Grzasko, Norbert
    Kumar, Shaji
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 89 - 98
  • [35] Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review
    Siddiqui, Abdul Aziz
    Khan, Kazi Najamus-saqib
    Farooqui, Arafat Ali
    Farooqi, Muhammad Saad
    Tariq, Muhammad Junaid
    Anwer, Faiz
    BLOOD, 2019, 134
  • [36] Practice Patterns in Front-line Treatment of Transplant-Eligible and Transplant-Ineligible Newly Diagnosed Multiple Myeloma
    Poy, Theprungsirikul
    Liu Yuxin
    Natalia, Neparidze
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S28 - S28
  • [37] Incidence, Timing, and Management of Infections in Patients Receiving Daratumumab for the Treatment of Newly Diagnosed Transplant-Ineligible Multiple Myeloma in the MAIA Study
    Bahlis, Nizar J.
    Facon, Thierry
    Usmani, Saad
    Moreau, Philippe
    Raje, Noopur
    Zweegman, Sonja
    Chari, Ajai
    Perrot, Aurore
    Manier, Salomon
    Orlowski, Robert
    Goldschmidt, Hartmut
    Basu, Supratik
    Hulin, Cyrille
    Weisel, Katja
    Mohty, Mohamad
    Plesner, Torben
    Cook, Gordon
    Leleu, Xavier
    Quach, Hang
    Venner, Christopher P.
    Ngo, Mai
    Bolyard, Kasey
    Carson, Robin
    Borgsten, Fredrik
    Kumar, Shaji
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S221 - S221
  • [38] Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
    Facon, Thierry
    San-Miguel, Jesus
    Dimopoulos, Meletios A.
    Mateos, Maria-Victoria
    Cavo, Michele
    van Beekhuizen, Sophie
    Yuan, Zijiao
    Mendes, Joao
    Lam, Annette
    He, Jianming
    Ammann, Eric
    Kumar, Shaji
    ADVANCES IN THERAPY, 2022, 39 (05) : 1976 - 1992
  • [39] Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
    Thierry Facon
    Jesús San-Miguel
    Meletios A. Dimopoulos
    Maria-Victoria Mateos
    Michele Cavo
    Sophie van Beekhuizen
    Zijiao Yuan
    João Mendes
    Annette Lam
    Jianming He
    Eric Ammann
    Shaji Kumar
    Advances in Therapy, 2022, 39 : 1976 - 1992
  • [40] Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study
    Mian, Hira S.
    Pond, Gregory R.
    Wildes, Tanya M.
    Sivapathasundaram, Branavan
    Sussman, Jonathan
    Seow, Hsien
    HAEMATOLOGICA, 2021, 106 (07) : 1991 - 1994
12345